-
Nov 20, 2024 | 
onclive.com | Douglas Sborov
Douglas Sborov, MD, discusses a brief overview of key clinical trials, including PERSEUS, IsKia, and GMMG-HD7, highlighting their implications for the treatment of patients with NDMM.
-
Nov 20, 2024 | 
onclive.com | Douglas Sborov
OpinionVideoNovember 20, 2024Author(s):Douglas Sborov, MD, discusses the most reported adverse events in transplant-eligible patients undergoing triplet or quadruplet therapy, as well as significant advancements on the horizon for frontline treatment in NDMM and key takeaways from recent clinical trial data that may impact clinical practice. Please comment on the most reported adverse events in TE patients undergoing triplet or quadruplet therapy.
-
Nov 20, 2024 | 
onclive.com | Douglas Sborov
OpinionVideoNovember 20, 2024Author(s):Douglas Sborov, MD, discusses how key factors, such as patient eligibility for ASCT, decision-making processes for patients with transplant-eligible NDMM, and the influence of depth of response, including MRD negativity, shape frontline therapy strategies. What factors guide your decision-making for TE patients with NDMM? How do you determine eligibility for ASCT?
-
Nov 11, 2024 | 
onclive.com | Douglas Sborov
“We need to be mindful of late neurological and gut toxicities. We monitor for changes that may be associated with facial nerve palsies, neuropathy, Parkinsonism, and significant changes in the gut.”Douglas W.
-
Oct 30, 2024 | 
onclive.com | Douglas Sborov
CommentaryVideoOctober 30, 2024Author(s):Fact checked by:,Douglas W. Sborov, MD, MS, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma. Douglas W.
-
Oct 11, 2024 | 
digitalcommons.library.tmc.edu | Ajai Chari |Jonathan Kaufman |Jacob P. Laubach |Douglas Sborov
The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities (HRCAs) per revised definition (del[17p], t[4;14], t[14;16], t[14;20], and/or gain/amp[1q21]).
-
Apr 11, 2024 | 
nature.com | Aimaz Afrough |Doris Hansen |Surbhi Sidana |Lauren C. Peres |Danai Dima |Joseph McGuirk | +6 more
Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].
-
Jan 24, 2024 | 
nature.com | Timothy Schmidt |Rafael Fonseca |Rajshekhar Chakraborty |Meera Mohan |Luciano Costa |Douglas Sborov | +1 more
AbstractExtra copies of chromosome 1q21 (+1q: gain = 3 copies, amp >= 4 copies) are associated with worse outcomes in multiple myeloma (MM). This systematic review assesses the current reporting trends of +1q, the efficacy of existing regimens on +1q, and its prognostic implications in MM randomized controlled trials (RCTs). Pubmed, Embase and Cochrane Registry of RCTs were searched from January 2012 to December 2022. Only MM RCTs were included.
-
Jan 22, 2024 | 
targetedonc.com | Douglas Sborov
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)Clinical Presentation:FH is a 54-year-old woman who presents to her physician with complaints of back pain, fatigue, nausea, constipation, and occasional, but recurring dizzinessInitial Clinical Workup and Diagnosis:Hb 7.0 g/dLCalcium 11.3 mg/dLCreatinine, 1.5 mg/dLAlbumin, 3.2 g/dLβ2-microglobulin, 6.0 mg/dLLDH 200 U/LBone marrow biopsy showed monoclonal plasma cells, 22%.
-
Jan 22, 2024 | 
targetedonc.com | Douglas Sborov
Case: A 54-Year-Old Woman with Newly Diagnosed Multiple Myeloma (NDMM)Clinical Presentation:FH is a 54-year-old woman who presents to her physician with complaints of back pain, fatigue, nausea, constipation, and occasional, but recurring dizzinessInitial Clinical Workup and Diagnosis:Hb 7.0 g/dLCalcium 11.3 mg/dLCreatinine, 1.5 mg/dLAlbumin, 3.2 g/dLβ2-microglobulin, 6.0 mg/dLLDH 200 U/LBone marrow biopsy showed monoclonal plasma cells, 22%.
